Holen Sie sich die Stockscreener-App
97.60
2.43%
-2.43
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com Nigeria
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Canada
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Dianthus Therapeutics (DNTH) Starts Phase 3 Trial, Is The Stock Still A Bargain? - Sahm
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
Dianthus Therapeutics stock hits 52-week high at 96.85 USD - Investing.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Dianthus launches phase 3 trial for myasthenia gravis treatment By Investing.com - Investing.com UK
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis - The Manila Times
Dianthus launches Phase 3 study of claseprubart in rare muscle disease - Stock Titan
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell Microcap Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Price to earnings forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Price to sales forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Enterprise value to EBIT forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
Dianthus Therapeutics Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Stock ReactionCost Structure Review - dars.gov.et
Price to book forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – DUS:87E - TradingView
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns - MSN
DNTH Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E) - TradingView
Top Damora Therapeutics, Inc. Common Stock (DMRA) Competitors 2026 - MarketBeat
A3ERZ4 Forecast — Price Target — Prediction for 2027 - TradingView
Dianthus Therapeutics Inc (DNTH) Valuation: PE, PB & Fair Value Analysis - TradingKey
Why is Dianthus Therapeutics stock trading higher on Friday? - MSN
DNTH Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares - Stock Titan
DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results - Stocktwits
Dianthus Therapeutics Inc (DNTH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DNTH Shares Surge 89% Over the Past Six Months: What's Driving It? - The Globe and Mail
Wells Fargo Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $135 - Moomoo
Dianthus Therapeutics Inc (DNTH) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dianthus Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | 87E | US2528281080 - marketscreener.com
Dianthus Therapeutics Inc (DNTH) Institutional Confidence - TradingKey
Dianthus Therapeutics Inc (DNTH) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dianthus Therapeutics Inc (DNTH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):